Blog
RSS FeedPosted by Michael Wonder on 14 Sep 2021
Branded price variation in the United States drug market, 2010 to 2019
13 September 2021 - Branded drug prices command considerable attention in the United States yet defining a drug’s price is not ...
Posted by Michael Wonder on 31 May 2021
External reference pricing: the drug pricing reform America needs?
27 May 2021 - External reference pricing, sometimes known as international reference pricing, refers to the practice of informing price negotiations ...
Posted by Michael Wonder on 25 May 2021
ICER publishes protocol for first annual assessment of drug coverage policies that present barriers to fair access
25 May 2021 - ICER’s analysis, based on MMIT’s market access analytics solution, will evaluate how 15 of the largest ...
Posted by Michael Wonder on 12 Apr 2021
International reference pricing for prescription drugs in the United States: administrative limitations and collateral effects
12 April 2021 - Many countries use international (or external) reference pricing—benchmarking prices against those in other countries—to manage spending ...
Posted by Michael Wonder on 12 Apr 2021
ICER publishes research protocol for assessing the unsupported price increases on prescription drugs that occurred in 2020
12 April 2021 - Final assessment to be published on 16 November; through 10 May, ICER is accepting public Input ...
Posted by Michael Wonder on 15 Feb 2021
Drug prices by committee: one way Biden could lower costs
11 February 2021 - Many countries use independent review boards to balance innovation and profit. ...
Posted by Michael Wonder on 12 Jan 2021
ICER identifies most significant 2019 US drug price hikes — even after rebates — that were not supported by new clinical evidence
12 January 2021 - Out of 10 identified drugs that had substantial 2019 price increases on top of already high current ...
Posted by Michael Wonder on 20 Oct 2020
Biden looks to Germany for answers on how to tackle high U.S. drug prices
20 October 2020 - With the U.S. election just two weeks away, Democratic presidential nominee Joe Biden is offering clues ...
Posted by Michael Wonder on 28 Sep 2020
ICER publishes white paper on cornerstones for fair patient access to prescription drugs, launches annual assessment of US payer policies
28 September 2020 - Informed by expert input from patient groups, clinician specialty societies, payers, and life science companies, white paper ...
Posted by Michael Wonder on 15 Aug 2020
Many psoriasis patients are paying higher prices than ever at the pharmacy counter
13 August 2020 - Over the past decade, wholesale prices for self-administered psoriasis medicines rose substantially, underscoring the ongoing financial ...
Posted by Michael Wonder on 02 Jul 2020
ICER publishes white paper on alternative policies for drug and vaccine pricing during a pandemic, announces cross-stakeholder discussion series
2 July 2020 - The Institute for Clinical and Economic Review today published a white paper to inform public and policy ...
Posted by Michael Wonder on 24 Jun 2020
ICER provides first update to pricing models for remdesivir as a treatment for COVID-19
24 June 2020 - Updated cost-recovery benchmark price now framed as a range with maximum of $1,600/10 day regimen when incorporating ...
Posted by Michael Wonder on 20 Jun 2020
ICER to assess whether the most significant prescription drug price increases are supported by new clinical evidence
19 June 2020 - Public input on drugs of concern will be accepted through 17 July 2020. ...
Posted by Michael Wonder on 08 Jun 2020
Fate of pharma’s reputation lies in Gilead’s hands on pricing of COVID-19 drug remdesivir
8 June 2020 - Few remember the time when the pharmaceutical industry was the world’s most admired. ...
Posted by Michael Wonder on 18 May 2020
International reference pricing gets thumbs down from ISPOR panel
18 May 2020 - International reference pricing, by which drug prices would be pegged to international standards, is under consideration ...